Effect of Glucagon on Fasting Insulin Secretion and Glucose Metabolism in Subjects Without Type 2 Diabetes

Description

Fasting hyperglycemia contributes disproportionately to nonenzymatic glycosylation and the microvascular complications of type 2 diabetes. However, little is known about the regulation of glucose concentrations in the fasting state relative to what is known about the postprandial state. The proposed experiment is part of a series of experiments designed to establish how glucagon and insulin interact with their receptors to control fasting glucose in health and in prediabetes.

Conditions

PreDiabetes

Talk to us

Study Overview

On this page

Study Details

Study overview

Fasting hyperglycemia contributes disproportionately to nonenzymatic glycosylation and the microvascular complications of type 2 diabetes. However, little is known about the regulation of glucose concentrations in the fasting state relative to what is known about the postprandial state. The proposed experiment is part of a series of experiments designed to establish how glucagon and insulin interact with their receptors to control fasting glucose in health and in prediabetes.

Effect of Glucagon on Fasting Insulin Secretion and Glucose Metabolism in Subjects Without Type 2 Diabetes

Effect of Glucagon on Fasting Insulin Secretion and Glucose Metabolism in Subjects Without Type 2 Diabetes

Condition
PreDiabetes
Intervention / Treatment

-

Contacts and Locations

Rochester

Mayo Clinic in Rochester, Rochester, Minnesota, United States, 55905

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Individuals with normal or impaired fasting glucose and normal or impaired glucose tolerance
  • * HbA1c less than 6.5%
  • * Use of any glucose-lowering agents including metformin or sulfonylureas.
  • * For female subjects: positive pregnancy test at the time of enrollment or study
  • * History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.
  • * Active systemic illness or malignancy.
  • * Symptomatic macrovascular or microvascular disease.

Ages Eligible for Study

25 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Mayo Clinic,

Adrian Vella, MD, PRINCIPAL_INVESTIGATOR, Mayo Clinic

Study Record Dates

2027-07-01